Shares of BioDelivery Sciences (BDSI) shoot up 33% premarket after the firm announces a...

|About: BioDelivery Sciences Inte... (BDSI)|By:, SA News Editor

Shares of BioDelivery Sciences (BDSI) shoot up 33% premarket after the firm announces a worldwide license and development agreement with Endo Pharmaceuticals (ENDP) for the rights to commercialize chronic pain treatment BEMA Buprenorphine.